Cellular Therapies in Chronic Lymphocytic Leukemia and Richter’s Transformation: Recent Developments in Chimeric Antigen Receptor T-Cells, Natural Killer Cells, and Allogeneic Stem...

por Coombs, Catherine C., Easaw, Saumya, Grover, Natalie S., O’Brien, Susan M.
Publicado 2023

Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis

por Bar-Or, Amit, O’Brien, Susan M., Sweeney, Michael L., Fox, Edward J., Cohen, Jeffrey A.
Publicado 2021

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

por O’Brien, Susan M., Brown, Jennifer R., Byrd, John C., Furman, Richard R., Ghia, Paolo, Sharman, Jeff P., Wierda, William G.
Publicado 2021

Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials

por Allan, John N., Shanafelt, Tait, Wiestner, Adrian, Moreno, Carol, O’Brien, Susan M., Li, Jianling, Krigsfeld, Gabriel, Dean, James P., Ahn, Inhye E.
Publicado 2021

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO...

por Kantarjian, Hagop M., DeAngelo, Daniel J., Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, O’Brien, Susan M., Jabbour, Elias, Wang, Tao, Liang White, Jane, Sleight, Barbara, Vandendries, Erik, Advani, Anjali S.
Publicado 2019

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL

por Jain, Nitin, Balakrishnan, Kumudha, Ferrajoli, Alessandra, O’Brien, Susan M., Burger, Jan A., Kadia, Tapan M., Cortes, Jorge E., Ayres, Mary L., Tambaro, Francesco Paolo, Keating, Michael J., Gandhi, Varsha, Wierda, William G.
Publicado 2016

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy

por Woyach, Jennifer A., Ghia, Paolo, Byrd, John C., Ahn, Inhye E., Moreno, Carol, O'Brien, Susan M., Jones, Daniel, Cheung, Leo W.K., Chong, Elizabeth, Kwei, Kevin, Dean, James P., James, Danelle F., Wiestner, Adrian
Publicado 2023

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab

por Kreuzer, Karl-Anton, Furman, Richard R., Stilgenbauer, Stephan, Dubowy, Ronald L., Kim, Yeonhee, Munugalavadla, Veerendra, Lilienweiss, Esther, Reinhardt, Hans Christian, Cramer, Paula, Eichhorst, Barbara, Hillmen, Peter, O’Brien, Susan M., Pettitt, Andrew R., Hallek, Michael
Publicado 2019

Management of adverse events associated with idelalisib treatment: expert panel opinion

por Coutré, Steven E., Barrientos, Jacqueline C., Brown, Jennifer R., de Vos, Sven, Furman, Richard R., Keating, Michael J., Li, Daniel, O’Brien, Susan M., Pagel, John M., Poleski, Martin H., Sharman, Jeff P., Yao, Nai-Shun, Zelenetz, Andrew D.
Publicado 2015

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib

por Jones, Jeffrey A., Hillmen, Peter, Coutre, Steven, Tam, Constantine, Furman, Richard R., Barr, Paul M., Schuster, Stephen J., Kipps, Thomas J., Flinn, Ian W., Jaeger, Ulrich, Burger, Jan A., Cheng, Mei, Ninomoto, Joi, James, Danelle F., Byrd, John C., O'Brien, Susan M.
Publicado 2017

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

por Jones, Jeffrey, Mato, Anthony, Coutre, Steven, Byrd, John C., Furman, Richard R., Hillmen, Peter, Osterborg, Anders, Tam, Constantine, Stilgenbauer, Stephan, Wierda, William G., Heerema, Nyla A., Eckert, Karl, Clow, Fong, Zhou, Cathy, Chu, Alvina D., James, Danelle F., O'Brien, Susan M.
Publicado 2018

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies

por Thompson, Philip A., Peterson, Christine B., Strati, Paolo, Jorgensen, Jeff, Keating, Michael J., O’Brien, Susan M., Ferrajoli, Alessandra, Burger, Jan A., Estrov, Zeev, Jain, Nitin, Kadia, Tapan M., Borthakur, Gautam, DiNardo, Courtney D., Daver, Naval, Jabbour, Elias, Wierda, William G.
Publicado 2018

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis

por O'Brien, Susan M., Byrd, John C., Hillmen, Peter, Coutre, Steven, Brown, Jennifer R., Barr, Paul M., Barrientos, Jacqueline C., Devereux, Stephen, Robak, Tadeusz, Reddy, Nishitha M., Kipps, Thomas J., Tedeschi, Alessandra, Cymbalista, Florence, Ghia, Paolo, Chang, Stephen, Ninomoto, Joi, James, Danelle F., Burger, Jan A.
Publicado 2019

Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

por Allan, John N., Pinilla-Ibarz, Javier, Gladstone, Douglas E., Patel, Krish, Sharman, Jeff P., Wierda, William G., Choi, Michael Y., O’Brien, Susan M., Shadman, Mazyar, Davids, Matthew S., Pagel, John M., Yimer, Habte A., Ward, Renee, Acton, Gary, Taverna, Pietro, Combs, Daniel L., Fox, Judith A., Furman, Richard R., Brown, Jennifer R.
Publicado 2021

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

por Sharman, Jeff P., Coutre, Steven E., Furman, Richard R., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian W., Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Tausch, Eugen, Cramer, Paula, Huang, Julie, Mitra, Siddhartha, Hallek, Michael, O’Brien, Susan M., Stilgenbauer, Stephan
Publicado 2019

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis

por Brown, Jennifer R., Moslehi, Javid, Ewer, Michael S., O'Brien, Susan M., Ghia, Paolo, Cymbalista, Florence, Shanafelt, Tait D., Fraser, Graeme, Rule, Simon, Coutre, Steven E., Dilhuydy, Marie‐Sarah, Cramer, Paula, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C., Treon, Steven, Liu, Emily Y., Chang, Stephen, Bista, Amulya, Vempati, Rama, Boornazian, Lisa, Valentino, Rudolph, Reddy, Vijay, Mahler, Michelle, Yang, Huiying, Graef, Thorsten, Burger, Jan A.
Publicado 2018

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

por Hillmen, Peter, Eichhorst, Barbara, Brown, Jennifer R., Lamanna, Nicole, O'Brien, Susan M., Tam, Constantine S., Qiu, Lugui, Kazmierczak, Maciej, Zhou, Keshu, Šimkovič, Martin, Mayer, Jiří, Gillespie-Twardy, Amanda, Shadman, Mazyar, Ferrajoli, Alessandra, Ganly, Peter S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Österborg, Anders, Yimer, Habte A., Salmi, Tommi, Ji, Meng, Yecies, Jessica, Idoine, Adam, Wu, Kenneth, Huang, Jane, Jurczak, Wojciech
Publicado 2023